Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 23:7:20.
doi: 10.20517/cdr.2024.25. eCollection 2024.

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Darin Poei  1 , Sana Ali  2 , Shirley Ye  1 , Robert Hsu  2
Affiliations
Review

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

Darin Poei et al. Cancer Drug Resist. .

Abstract

Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.

Keywords: ALK TKI; NSCLC; acquired resistance; alectinib; brigatinib; ceritinib; crizotinib; lorlatinib.

PubMed Disclaimer

Conflict of interest statement

Hsu R is a consultant for Targeted Oncology and Takeda and received honoraria from DAVA Oncology and The Dedham Group. All other authors declared that there are no conflicts of interest.

Figures

Figure 1
Figure 1
ALK TKI Chemical Structure[37]. Created by BioRender.com. Authors were granted a license to use BioRender content with copyright permission. ALK: Anaplastic lymphoma kinase; TKI: tyrosine kinase inhibitor.
See this image and copyright information in PMC

References

    1. Barlesi F, Mazieres J, Merlio JP, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Lancet. 2016;387:1415–26. doi: 10.1016/s0140-6736(16)00004-0. - DOI - PubMed
    1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006. doi: 10.1001/jama.2014.3741. - DOI - PMC - PubMed
    1. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4. doi: 10.1126/science.8122112. - DOI - PubMed
    1. Wellstein A. ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers. Front Oncol. 2012;2:192. doi: 10.3389/fonc.2012.00192. - DOI - PMC - PubMed
    1. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58. doi: 10.1186/s12943-018-0782-4. - DOI - PMC - PubMed

LinkOut - more resources